SSRX 3SBio Inc. featured news, full reports, and detailed charts
3SBio Inc. (SSRX) Wrap Up:
3SBio, Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in the People’s Republic of China. Its product candidates are designed to address unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company’s principal product, EPIAO is an injectable recombinant human erythropoietin that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. It also offers TPIAO, a recombinant human thrombopoietin indicated for the treatment of chemotherapy-induced thrombocytopenia, a deficiency of plat...3SBio Inc. (SSRX:NASDAQ)
Snapshot of 3SBio Inc. (SSRX)
|
OPEN
$12.11
|
PREVIOUS CLOSE
$12.10
|
|
|
DAY HIGH
$13.01
|
DAY LOW
$12.11
|
|
|
52 WEEK HIGH
11/20/09 - $13.01
|
52 WEEK LOW
03/12/09 - $4.18
|
|
|
MARKET CAP
276.0M
|
AVERAGE VOLUME 3 mo
96.7K
|
|
|
DILUTED EPS TTM
$0.50
|
SHARES OUTSTANDING
21.5M
|
|
|
SSRX Does Not Pay Dividends
|
P/E TTM
25.8x
|
|
| K = Thousands M = Millions B = Billions | ||
SSRX Top Compensated Officers
Executives, Board Directors
Key developments for 3SBio Inc. (SSRX)
3SBio Inc. announced operating cash flow for the third quarter ended September 30, 2009. For the quarter, the company's operating cash flow was $9 million.
3SBio Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. Net revenues increased by 35.8% to RMB 92.6 million ($13.6 million) for the third quarter of 2009 from RMB 68.2 million ($10.0 million) for the same period in 2008. This increase was largely due to continued strength from EPIAO and TPIAO products, which increased by 32.6% and 41.3%, respectively, over the same period in 2008. GAAP operating income was RMB 28.5 million ($4.2 million) for the third quarter of 2009, an increase of 37.8% from operating income of RMB 20.7 million ($3.1 million) for the same period in 2008. Non-GAAP operating income for the third quarter of 2009 grew by 34.7% to RMB 29.8 million ($4.4 million), compared to RMB 22.1 million ($3.3 million) in the third quarter of 2008. The company recorded net interest income of RMB 2.6 million ($0.4 million) for the third quarter of 2009, compared to RMB 5.5 million ($0.8 million) for the same period in 2008. GAAP net income was RMB 26.9 million ($3.9 million) for the third quarter of 2009, 1,343.5% higher than net income of RMB 1.9 million ($0.3 million) for the same period in 2008. GAAP net income per ADS on a fully-diluted basis for the third quarter of 2009 increased to RMB 1.25 ($0.18) from RMB 0.09 ($0.01) for the same period in 2008. Non-GAAP net income for the third quarter of 2009 was RMB 28.2 million ($4.1 million), 25.6% higher than non-GAAP net income of RMB 22.4 million ($3.3 million) for the same period in 2008. Non-GAAP net income per ADS on a fully diluted basis for the third quarter of 2009 increased to RMB 1.31 ($0.19) from RMB 1.03 ($0.15) for the same period in 2008. The company reported GAAP income before income tax expense of RMB 31.392 million ($4.592 million), non-GAAP income before income tax expense of RMB 32.625 ($4.778 million), net income per basic and diluted share of RMB 0.18 ($0.03) and non-GAAP income per basic and diluted share of RMB 0.19 ($0.03) compared to GAAP income before income tax expense and minority interests of RMB 6.060 million ($0.893 million), non-GAAP income before income tax expense of RMB 26.604 ($3.918 million), net income per basic and diluted share of RMB 0.01 ($0.00) and non-GAAP income per basic and diluted share of RMB 0.15 ($0.02) for the same period of last year. Net revenues for the first nine months of 2009 increased by 32.5% to RMB 242.6 million ($35.5 million), from RMB 183.2 million ($27.0 million) for the same period in 2008. The increase was primarily attributable to increased sales from EPIAO and TPIAO products, underpinned by continued strong demand in the oncology and nephrology markets. For the first nine months ended September 30, 2009, GAAP operating income increased by 48.6% to RMB 74.5 million ($10.9 million), compared to RMB 50.1 million ($7.4 million) for the same period in 2008. Non- GAAP operating income increased by 44.3% to RMB 77.5 million ($11.4 million), compared to RMB 53.7 million ($7.9 million) for the same period in 2008. GAAP net income for the first nine months of 2009 increased by 70.2% to RMB 69.8 million ($10.2 million) compared with RMB 41.0 million ($6.0 million) for the same period in 2008. GAAP net income per ADS on a fully diluted basis for the first nine months of 2009 increased to RMB 3.24 ($0.47) from RMB 1.89 ($0.28) for the same period in 2008. Non-GAAP net income for the first nine months of 2009 increased by 19.0% to RMB 75.8 million ($11.1 million) compared with RMB 63.7 million ($9.4 million) for the same period in 2008. Non-GAAP net income per ADS for the first nine months of 2009 increased to RMB 3.52 ($0.52) from RMB 2.93 ($0.43) for the same period in 2008. The company reported GAAP income before income tax expense of RMB 82.344 million ($12.064 million), non-GAAP income before income tax expense of RMB 88.367 ($12.947 million), net income per basic and diluted share of RMB 0.46 ($0.07) and non-GAAP income per basic and diluted share of RMB 0.50 ($0.07) compared to GAAP income before income tax expense and minority interests of RMB 52.020 million ($7.660 million), non-GAAP income before income tax expense of RMB 74.745 ($11.006 million), net income per basic and diluted share of RMB 0.27 ($0.04) and non-GAAP income per basic and diluted share of RMB 0.42 ($0.06) for the same period of last year. Based on current market conditions and visibility provided during the third quarter, the Company reiterates its total net revenue target for the full year of 2009 of between $43 million to $45 million, resulting in a year-over-year increase of approximately 21% to 26%.
3SBio Inc., Q3 2009 Earnings Call, Nov 13 2009
SSRX Competitors
| Company | Last | Change |
| Kirin Holdings Company Limited | ¥1,377 JPY | -16.00 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | SSRX | Industry Range |
| Price/Earnings | 26.0x |
|
| Price/Sales | 5.9x |
|
| Price/Book | 1.8x |
|
| Price/Cash Flow | 26.0x |
|
| TEV/Sales | 3.5x |
|
|
SSRX |
||
SSRX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About 3SBio Inc.
More news for SSRX
3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009
SHENYANG, China, Oct. 27 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX - News; "3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the third quarter ended September 30, 2009 after the US market closes on Thursday, November 12, 2009. Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong) on Friday, November 13, 2009 to discuss its 2009 third quarter financial results and recent business activity. The conference call may be accessed using the dial-in numbers below: Conference ID: 38479039 Local dial-in: China - landline 800-819-0121 China - mobile 400-620-8038 International toll-free dial-in: Hong Kong 800930346 United Kingdom 080-8234-6646 United States 1-866-519-4004 International toll dial-in: 65-6735-7955 Replay-Conference ID: 38479039 A telephone replay will be available two hours after the call until November 20, 2009, at: International dial-in: +61-2-8235-5000 United States dial-in: 1-866-214-5335 WebcastA live webcast of the conference will be available on the investor relations page of 3SBio's website at ...Click here to read the whole Article (external link)
3SBio Inc. Announces Results of Annual General Meeting
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
3SBio Inc. Announces Unaudited Third Quarter 2009 Results
SHENYANG, China, Nov. 12 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX - News; "3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the third quarter ended September 30, 2009. Third Quarter 2009 Financial Highlights: -- Total net revenues increased by 35.8% over the third quarter of 2008 to RMB92.6 million (US$13.6 million). -- Operating income increased by 37.8% over the third quarter of 2008 to RMB28.5 million (US$4.2 million) on a GAAP basis, and increased by 34.7% over the third quarter of 2008 to RMB29.8 million (US$4.4 million) on a non-GAAP basis. -- Net income increased by 1343.5% over the third quarter of 2008 to RMB26.9 million (US$3.9 million) on a GAAP basis, and increased by 25.6% over the third quarter of 2008 to RMB28.2 million (US$4.1 million) on a non-GAAP basis. -- Net income per American Depositary Share ("ADS") for the third quarter of 2009 was RMB1.25 (US$0.18) compared with RMB0.09 (US$0.01) for the third quarter of 2008 on a GAAP basis, and RMB1.31 (US$0.19) for the third quarter of 2009 compared with RMB1.03 (US$0.15) for the third quarter of 2008 on a non-GAAP basis. First Nine Months 2009 Financial Highlights: -- Total net revenues in the first nine months of 2009 increased by 32.5% to RMB242.6 million (US$35.5 millio...Click here to read the whole Article (external link)
Q3 2009 3SBIO INC Earnings Release - After Market Close
Earnings Announcements for Thursday, November 12CompanySymbolTimeConferenceCall3i Group plcIII.LBefore Market Open3SBIO INCSSRXAfter Market CloseListenA.D.A.M., Inc.ADAMTime Not SuppliedListenA2A SpAA2A.MITime Not SuppliedAcciona, S.A.ACXIF.PKBefore Market OpenACSM S P AACS.MITime Not SuppliedADDUS HOMECARE CORPADUSBefore Market OpenListenAdvanSource Biomaterials CorporationASBTime Not SuppliedADVANTAGE OIL & GAS LTDAAVAfter Market CloseAECOMACMBefore Market OpenListenAEFFE SPAAEF.MITime Not SuppliedAEGON N.V.AEGOF.PK01:30 am ETAFC Enterprises, Inc.AFCEAfter Market CloseListenAG GROWTH INTL INCAFN.TOBefore Market OpenAir Transport Services Group, Inc.ATSGTime Not SuppliedListenAldila, Inc.ALDAAfter Market CloseALEO SOLAR AG...Click here to read the whole Article (external link)
3SBio Inc. Q3 2009 Earnings Call Transcript
3SBio Inc. (SSRX) Q3 2009 Earnings Call November 13, 2009 8:00 am ET Executives Jing Lou - Chief Executive Officer Bo Tan - Chief Financial Officer David Chen - Chief Operating Officer Yingfei Wei - Chief Scientific Officer Kevin Teo - Director of Finance Tom Folinsbee - Director of Investor Relations Analysts Hongbo Lu - Piper Jaffray [Ram Balarasu - Soleil Securities] Katherine Lu - Oppenheimer Cheng Hu - Mentor Capital Jeb Besser - Manchester Management Presentation Operator Welcome to the 3SBio, quarter three 2009 earnings conference call. At this time, all participants are in a listen-only mode. (Operator Instructions) I would now like to hand the conference over to your speaker today, Mr. Tom Folinsbee. Thank you. Please go ahead. Tom Folinsbee Welcome to 3SBio’s third quarter 2009 results conference call. Before I turn the call over to the management team, I would like to remind you that the presentation today may contain forward-looking statements made pursuant to the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks, uncertainties and assumptions. As such 3SBio’s actual financial condition and operation results may differ materially from those forward looking statements. A number of risks and uncertainties that are discussed in our risk factors and other relevant sections of 3SBio’s filings with the Securities and Exchange Commission. Please see the earnings press release under the heading Safe Harbor statement for more information. 3SBio undertakes no obligation to update or revise these forward-looking statements. As the management team proceeds through their r...Click here to read the whole Article (external link)
3SBIO INC Earnings Call scheduled for 8:00 am ET today
Call Details3SBIO INC Earnings Conference Call (Q3 2009)Fri, Nov 13, 2009, 8:00 am EasternAbout 3SBIO INC (NasdaqGS:SSRX)3SBio Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in the Peoples Republic of China. Its products are designed to address unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The companys principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin product to treat chemotherapy-induced thrombocytopenia, a deficiency of platelets. 3SBio also offers protein-based therapeutics, such as Intefen, a recombinant human interferon alpha-2a product for malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; and Inleusin, a recombinant human interleukin-2 product for renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused by cancer and tuberculosis. In addition, it markets Tietai Iron Sucrose Supplement, an in-licensed product for the treatment of anemia. The companys product pipeline comprises Ferumoxytol, a next generation intravenous iron; a high dose (36,000 IU/vial) formulation EPIAO; and NuPIAO, a second-generation EPIAO product candidate. Its product pipeline also consists of NuLeusin, a next-generation Inleusin product candidate; TPIAO for idiopathic thrombocytopenic purpura; a human papilloma virus vaccine to prevent cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for rheumatoid arthritis and other autoimmune diseases. 3SBio sells its products through distributors to hospitals, clinics, and dialysis centers, as w...Click here to read the whole Article (external link)
